Hormonal
GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly in obese individuals undergoing rapid weight loss, though the risk for pancreatitis is not consistently supported by recent large-scale data.
Be aware that GLP-1 medications slightly increase the risk of gallbladder issues, especially if you lose weight quickly. However, recent data suggests the risk of pancreatitis is not significantly higher than with other treatments. Discuss your personal risk factors with your doctor, who may recommend monitoring.
GLP-1 RA use was reported to increase the risk of gallbladder stones or biliary tract disease by 37%... current body of evidence suggests that... more robust and contemporary data do not demonstrate a consistent or clinically meaningful increase in pancreatitis risk associated with GLP-1 RA therapy.
Why this rating
Based on meta-analyses of RCTs and observational studies, though findings are heterogeneous.
Source
Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
Nimet Yılmaz et al. · Diabetes Metabolic Syndrome and Obesity · 2026
DOI 10.2147/dmso.s584175
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →